Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22999897 | 0.94 | USP2 (0.42) | USP2SMN1; SMN2DDB1CRBNMAPT | |
| SCHEMBL648569 | 0.92 | CYP11B2 (0.41) | USP2SMN1; SMN2DDB1CRBNPIK3R1 | |
| SCHEMBL24582054 | 0.87 | USP2 (0.41) | USP2SMN1; SMN2DDB1CRBNMAPT | |
| SCHEMBL3327975 | 0.84 | HPGD (0.49) | USP2SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL15491798 | 0.83 | HPGD (0.51) | USP2SMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL10092901 | 0.83 | USP2 (0.45) | USP2ALDH1A1TSHRALOX15 | |
| SCHEMBL24197190 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2DDB1CRBNMAPT | |
| SCHEMBL2959763 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2DDB1CRBNMAPT | |
| SCHEMBL31028 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2DDB1CRBNMAPT | |
| SCHEMBL27669441 | 0.82 | USP2 (0.56) | USP2SMN1; SMN2DDB1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| US-8034933-B2 | graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090028818-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-01-29 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442703-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384948-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076078-A1 | New compounds 966 | OPRM1, OPRL1, OPRK1 | USP2 4603/4885SMN1; SMN2 295/4885DDB1 4589/4885 |
| US-20090028818-A1 | Heterocyclic antiviral compounds | CCR5, CCR1, CCR2 | USP2 3943/4885SMN1; SMN2 3036/4885DDB1 2166/4885 |
| US-20080214575-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CCR10, CXCR3 | USP2 4689/4885SMN1; SMN2 3139/4885DDB1 4706/4885 |
| US-20140057895-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | HTR4, HTR3B, HTR3A | USP2 4682/4885SMN1; SMN2 4165/4885DDB1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.